Autonomix licenses FDA-cleared ablation technology; issues 250,000 shares to RF Innovations

Autonomix Medical, Inc.

Licensed intellectual property for Apex 6 Radiofrequency Generator, an FDA-cleared ablation device for peripheral nerve pain.
Consideration is 250,000 shares of common stock; license is perpetual, non-exclusive, worldwide, and royalty-free.
Transaction expected to close before the end of July 2024; manufacturing partner to be integrated into supply chain.
Technology supports Autonomix's development for pancreatic cancer pain and other indications, potentially simplifying regulatory pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.